Next-Generation Ototoxicity Prevention System
Legal Citation
Summary of the Inventive Concept
A wearable, personalized, and targeted system for preventing platinum-induced ototoxicity in cancer patients, leveraging advanced delivery technologies and AI-driven analytics.
Background and Problem Solved
The original patent disclosed hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent, but these compositions have limitations in terms of delivery, efficacy, and personalized treatment. The new inventive concept addresses these limitations by introducing a wearable device, nanochannel delivery system, and machine learning algorithms to prevent ototoxicity more effectively.
Detailed Description of the Inventive Concept
The system comprises a wearable device for delivering a hypertonic pharmaceutical composition containing an anti-platinum chemoprotectant agent to the subject's ear, a nanochannel delivery system for targeted delivery to specific cells in the cochlea, and a machine learning algorithm for analyzing otoacoustic emission data to predict the likelihood of hearing loss. The system also includes a genetic testing module for identifying genetic markers associated with increased risk of hearing loss, enabling personalized prevention.
Novelty and Inventive Step
The new inventive concept introduces a paradigm shift in ototoxicity prevention by integrating wearable technology, nanochannel delivery, and AI-driven analytics, which are not present in the original patent. The combination of these elements provides a more effective, personalized, and targeted approach to preventing platinum-induced ototoxicity.
Alternative Embodiments and Variations
Alternative embodiments of the system could include implantable devices, transdermal patches, or oral formulations, each with its own advantages and limitations. Variations of the system could also include different types of sensors, machine learning algorithms, or genetic testing modules to further enhance its performance and versatility.
Potential Commercial Applications and Market
The Next-Generation Ototoxicity Prevention System has significant commercial potential in the oncology and pharmaceutical industries, with a target market of cancer patients undergoing platinum-based chemotherapy. The system's ability to prevent ototoxicity could improve patient outcomes, reduce healthcare costs, and enhance quality of life.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical Formulations and Medical Device Technologies, with specialized expertise in chemotherapy-related ototoxicity prevention, drug delivery systems, and personalized medical interventions
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences, biomedical engineering, or related fields, possessing knowledge of drug formulation, targeted delivery technologies, and medical device design with understanding of chemotherapy side effect mitigation
Obviousness Rationale
A person having ordinary skill would recognize that the PTD represents a predictable extension of the source patent's core technology by applying known drug delivery and monitoring techniques to the specific problem of platinum-induced ototoxicity. The variations demonstrate standard engineering problem-solving approaches that combine existing technologies in a logical, incremental manner. The PTD's innovations represent routine optimization of the original pharmaceutical composition through well-understood technological augmentations.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,567 |
|---|---|
| Title | Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent |
| Assignee(s) | Decibel Therapeutics, Inc. |